{"entity":{"id":"nct06747338","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","aka":[],"tldr":"A phase 3 trial testing HB1801 in HER2-positive breast cancer, active and no longer recruiting.","summary":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT06747338, led by Shanghai JMT-Bio, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer. Planned enrolment is 520 participants (estimated). The study started in 2024-12-16 and primary completion is expected in 2026-12-16. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06747338","url":"https://clinicaltrials.gov/study/NCT06747338"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["hb1801","kn026"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct06747338-jama-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06747338","phase":"3","setting":"A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer","sponsor":"Shanghai JMT-Bio","started":"2024-12-16","startedType":"actual","enrolled":520,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06747338/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"hb1801","kind":"drug","name":"HB1801","route":"/drugs/hb1801/"},{"id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}],"paper":[{"id":"paper-nct06747338-jama-oncol-2026","kind":"paper","name":"Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct06747338-jama-oncol-2026/"}]}}